v3.22.4
ACCRUED EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consist of the following (in thousands):
 December 31,
 20222021
Accrued selling, general and administrative expenses$11,927 $12,063 
Accrued research and development expenses4,065 5,480 
Other accrued operating expenses14,959 14,912 
Compensation and benefits (1)
26,198 45,491 
Termination fee (2)
13,000 — 
Accrued royalties (3)
3,400 35,298 
Accrued interest8,941 5,358 
Product returns and wholesaler service fees7,295 8,953 
Total$89,785 $127,555 
(1) At December 31, 2021, compensation and benefits included $18.4 million of accrued severance associated with the Flexion Acquisition.
(2) See Note 20, Commitments and Contingencies, for more information.
(3) At December 31, 2021, accrued royalties included a $32.0 million milestone payment to Skyepharma that was met in the fourth quarter of 2021 for achieving annual net sales collected of $500.0 million on the Company’s DepoBupivacaine products, including EXPAREL. This milestone was paid in the first quarter of 2022. See Note 9, Goodwill and Intangible Assets, for more information